Epruvy 10 mg/ml oplossing voor injectie
As listed in the register: Epruvy 10 mg/ml oplossing voor injectie
10 mg/ml · oplossing voor injectie
- Prescription only
- Eyes and ears
- Active substance
- Ranibizumab
- Used in
- Eyes and ears
- Made by
- Midas Pharma GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (LUCENTIS). It describes the substance, not this exact product.
Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110.
VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-11-21
Safety of the active substance
From the US prescribing label for the same active substance (LUCENTIS). It describes the substance, not this exact product.
- Ocular or periocular infections ( 4.1 ) Hypersensitivity ( 4.2 ) 4.1 Ocular or Periocular Infections LUCENTIS is contraindicated in patients with ocular or periocular infections. 4.2 Hypersensitivity LUCENTIS is contraindicated in patients with known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.
- Hypersensitivity reactions may manifest as severe intraocular inflammation.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Spain14 matching products
- LUCENTIS 10 MG/ML · solución inyectable3 makers
- BYOOVIZ 10 MG/ML · solución inyectable2 makers
- RANIVISIO 10 MG/ML · solución inyectable2 makers
- RANLUSPEC 10 mg/ml · solución inyectable2 makers
- REXATILUX 10 mg/ml · solución inyectable2 makers
- RIMMYRAH 10 mg/ml · solución inyectable2 makers
- XIMLUCI 10 MG/ML · solución inyectable
France7 matching products
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Midas Pharma GmbH |
|---|---|
| Active substance | Ranibizumab |
| Used in | Eyes and ears |
| Strength | 10 mg/ml |
| Form | oplossing voor injectie |
| Classification | S01LA04 · Eyes and ears |
| Route | intravitreaal gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| RVG | EU/1/24/1860 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.